{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:56:00Z","timestamp":1761562560508},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pegylated liposomal doxorubicin plays an important role in the treatment of patients with severe refractory human immunodeficiency virus (HIV)-associated Kaposi sarcoma (KS). High cumulative doses of conventional doxorubicin exceeding 500\u2009mg\/m<jats:sup>2<\/jats:sup> are known to cause cardiac toxicity. However, the safe cumulative dose of pegylated liposomal doxorubicin is unclear.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 40-year-old Japanese man with HIV infection presented with pain, edema, and multiple skin nodules on both legs which worsened over several months. He was diagnosed with HIV-associated KS. He received long-term pegylated liposomal doxorubicin combined with antiretroviral therapy for advanced, progressive KS. The cumulative dose of pegylated liposomal doxorubicin reached 980\u2009mg\/m<jats:sup>2<\/jats:sup>. The patient\u2019s left ventricular ejection fraction remained unchanged from baseline during treatment. After he died as a result of cachexia and wasting, caused by recurrent sepsis and advanced KS, an autopsy specimen of his heart revealed little or no evidence of histological cardiac damage. We also conducted a literature review focusing on histological changes of the myocardium in patients treated with a cumulative dose of pegylated liposomal doxorubicin exceeding 500\u2009mg\/m<jats:sup>2<\/jats:sup>.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This case report and literature review suggest that high (&gt;\u2009500\u2009mg\/m<jats:sup>2<\/jats:sup>) cumulative doses of pegylated liposomal doxorubicin may be used without significant histological\/clinical cardiac toxicity in patients with HIV-associated KS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-019-4500-7","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T17:30:03Z","timestamp":1571160603000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Histological evidence for the cardiac safety of high-dose pegylated liposomal doxorubicin in a patient with HIV-associated Kaposi sarcoma: a case report and literature review"],"prefix":"10.1186","volume":"19","author":[{"given":"Ayaka","family":"Ishihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Amano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teppei","family":"Sasahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Toshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Morisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"4500_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1200\/JCO.2013.51.6757","volume":"32","author":"M Bower","year":"2014","unstructured":"Bower M, Dalla Pria A, Coyle C, Andrews E, Tittle V, Dhoot S, et al. Prospective stage-stratified approach to AIDS-related Kaposi's sarcoma. J Clin Oncol. 2014;32:409\u201314.","journal-title":"J Clin Oncol"},{"key":"4500_CR2","unstructured":"Katano H, Imamura A, Kato H, Ozawa K, Nagata N, Teruya K, et al. Diagnosis and guidance on HHV-8 related diseases such as AIDS related Kaposi sarcoma. \n                    http:\/\/www.acc.go.jp\/doctor\/010\/020\/HHV8_tebiki201403.pdf\n                    \n                   [accessed 17 May 2019]."},{"key":"4500_CR3","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1002\/cncr.25362","volume":"116","author":"M Cianfrocca","year":"2010","unstructured":"Cianfrocca M, Lee S, Von Roenn J, Tulpule A, Dezube BJ, Aboulafia DM, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer. 2010;116:3969.","journal-title":"Cancer."},{"key":"4500_CR4","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1097\/01.aids.0000131385.60974.b9","volume":"18","author":"L Martin-Carbonero","year":"2004","unstructured":"Martin-Carbonero L, Barrios A, Saballs P, Sirera G, Santos J, Palacios R, et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS. 2004;18:1737\u201340.","journal-title":"AIDS."},{"key":"4500_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/cncr.10634","volume":"95","author":"A Tulpule","year":"2002","unstructured":"Tulpule A, Groopman J, Saville MW, Harrington W Jr, Friedman-Kien A, Espina BM, et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer. 2002;95:147\u201354.","journal-title":"Cancer"},{"key":"4500_CR6","unstructured":"Prescribing Information for DOXORUBICIN HYDROCHLORIDE. U.S. Food and Drug Administration. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/050467s073lbl.pdf\n                    \n                   [accessed 17 May 2019]."},{"key":"4500_CR7","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O'Brien","year":"2004","unstructured":"O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. CAELYX breast Cancer study group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440\u20139.","journal-title":"Ann Oncol"},{"key":"4500_CR8","unstructured":"Prescribing Information for DOXIL. U.S. Food and Drug Administration. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/050718s051lbl.pdf\n                    \n                   [accessed 17 May 2019]."},{"key":"4500_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.idcr.2015.05.001","volume":"2","author":"J Suzuki","year":"2015","unstructured":"Suzuki J, Sasahara T, Toshima M, Norizuki M, Onishi T, Okabe T, et al. Usefulness of 18F-Fluorodeoxyglucose-position emission tomography with computed tomography and gallium-67 scintigraphy for detection of Kaposi sarcoma lesions in a 40-year-old Japanese man with AIDS. IDCases. 2015;2:68\u20139.","journal-title":"IDCases."},{"key":"4500_CR10","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1200\/JCO.1989.7.9.1201","volume":"7","author":"SE Krown","year":"1989","unstructured":"Krown SE, Metroka C, Wernz JC. Kaposi\u2019s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group oncology committee. J Clin Oncol. 1989;7:1201\u20137.","journal-title":"J Clin Oncol"},{"key":"4500_CR11","first-page":"567","volume":"2","author":"AM Rahman","year":"2007","unstructured":"Rahman AM, Yusuf SW, Ewer MS. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomedicine. 2007;2:567\u201383.","journal-title":"Int J Nanomedicine"},{"key":"4500_CR12","first-page":"865","volume":"62","author":"ME Billingham","year":"1978","unstructured":"Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978;62:865\u201372.","journal-title":"Cancer Treat Rep"},{"key":"4500_CR13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.7326\/0003-4819-88-2-168","volume":"88","author":"MR Bristow","year":"1978","unstructured":"Bristow MR, Mason JW, Billingham ME, Daniels JR. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med. 1978;88:168\u201375.","journal-title":"Ann Intern Med"},{"key":"4500_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3109\/10611869609015970","volume":"4","author":"PG Tardi","year":"1996","unstructured":"Tardi PG, Boman NL, Cullis PR. Liposomal doxorubicin. J Drug Target. 1996;4:129\u201340.","journal-title":"J Drug Target"},{"key":"4500_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.10201","volume":"94","author":"L Harris","year":"2002","unstructured":"Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, et al. TLC D-99 study group. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002;94:25\u201336.","journal-title":"Cancer."},{"key":"4500_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/0014-5793(90)81016-H","volume":"268","author":"AL Klibanov","year":"1990","unstructured":"Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethylenglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990;268:235\u20137.","journal-title":"FEBS Lett"},{"key":"4500_CR17","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312\u201322.","journal-title":"J Clin Oncol"},{"key":"4500_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ygyno.2004.03.024","volume":"94","author":"D Uyar","year":"2004","unstructured":"Uyar D, Kulp B, Peterson G, Zanotti K, Markman M, Belinson J. Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies. Gynecol Oncol. 2004;94:147\u201351.","journal-title":"Gynecol Oncol"},{"key":"4500_CR19","first-page":"1414","volume":"97","author":"Y Collins","year":"2005","unstructured":"Collins Y, Lele S. Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma. J Natl Med Assoc. 2005;97:1414\u20136.","journal-title":"J Natl Med Assoc"},{"key":"4500_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000312644","volume":"56","author":"JP Kesterson","year":"2010","unstructured":"Kesterson JP, Odunsi K, Lele S. High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies. Chemotherapy. 2010;56:108\u201311.","journal-title":"Chemotherapy."},{"key":"4500_CR21","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/aogs.12642","volume":"94","author":"A Rabinovich","year":"2015","unstructured":"Rabinovich A, Ramanakumar AV, Lau S, Gotlieb WH. Prolonged pegylated liposomal doxorubicin treatment for recurrent pelvic cancers: a feasiability study. Acta Obstet Gynecol Scand. 2015;94:776\u201380.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"4500_CR22","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0959-8049(01)00053-3","volume":"37","author":"UR Hengge","year":"2001","unstructured":"Hengge UR, Esser S, Rudel HP, Goos M. Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin. Eur J Cancer. 2001;37:878\u201383.","journal-title":"Eur J Cancer"},{"key":"4500_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/sj.bjc.6601904","volume":"91","author":"F Pein","year":"2004","unstructured":"Pein F, Sakiroglu O, Dahan M, Lebidois J, Merlet P, Shamsaldin A, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer. 2004;91:37\u201344.","journal-title":"Br J Cancer"},{"key":"4500_CR24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00280-017-3420-8","volume":"80","author":"KM Skubitz","year":"2017","unstructured":"Skubitz KM, Blaes AH, Konety SH, Francis GS. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value. Cancer Chemother Pharmacol. 2017;80:787\u201398.","journal-title":"Cancer Chemother Pharmacol"},{"key":"4500_CR25","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1023\/A:1008216430806","volume":"9","author":"G Berry","year":"1998","unstructured":"Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi\u2019s sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol. 1998;9:711\u20136.","journal-title":"Ann Oncol"},{"key":"4500_CR26","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1081\/CNV-200032899","volume":"22","author":"AA Gabizon","year":"2004","unstructured":"Gabizon AA, Lyass O, Berry GJ, Wildgust M. Cardiac safety of pegylated liposomal doxorubicin (Doxil\/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Investig. 2004;22:663\u20139.","journal-title":"Cancer Investig"},{"key":"4500_CR27","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1023\/A:1008365716693","volume":"11","author":"T Safra","year":"2000","unstructured":"Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg\/m2. Ann Oncol. 2000;11:1029\u201333.","journal-title":"Ann Oncol"},{"key":"4500_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fmicb.2012.00073","volume":"3","author":"MN Polizzotto","year":"2012","unstructured":"Polizzotto MN, Uldrick TS, Hu D, Yarchoan R. Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome. Front Microbiol. 2012;3:73.","journal-title":"Front Microbiol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4500-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4500-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4500-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T23:08:46Z","timestamp":1602630526000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4500-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4500"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4500-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]},"assertion":[{"value":"28 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The parents of the patient provided written informed consent for publication of this report according to the patient\u2019s consent given prior to death.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"848"}}